Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Plos One|February 8, 2024
Real-World evidence revelations: The potential of patient support programmes to provide data on medication usageEszter Palffy, David John LewisTherapeutic Innovation & Regulatory Science|September 19, 2018
The Enigma of Pharmacovigilance of Patient Support Programs: A Survey of Marketing Authorization Holders in EuropeJamie Michelle Portnoff, David John LewisTherapeutic Innovation & Regulatory Science|June 20, 2020
Utilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and OpportunitiesDavid John Lewis, John Fraser McCallumTherapeutic Innovation & Regulatory Science|June 21, 2023
Pharmacovigilance Agreements: Negotiating Safety Data Exchange Timelines: To Agree to Disagree? That is the QuestionWendy Manko Singer, Elizabeth MacEntee Pileggi, Yvonne Gibble, et al.Therapeutic Innovation & Regulatory Science|May 2, 2018
Risk of Cleft Lip and/or Palate Associated With Antiepileptic Drugs: Postmarketing Safety Signal Detection and Evaluation of Information Presented to Prescribers and PatientsBita Rezaallah, David John Lewis, Hans-Florian Zeilhofer, et al.Journal of Medical Internet Research|February 20, 2020
Correction: Social Media Surveillance of Multiple Sclerosis Medications Used During Pregnancy and Breastfeeding: Content AnalysisBita Rezaallah, David John Lewis, Carrie Pierce, et al.Journal of Medical Internet Research|August 9, 2019
Social Media Surveillance of Multiple Sclerosis Medications Used During Pregnancy and Breastfeeding: Content AnalysisBita Rezaallah, David John Lewis, Carrie Pierce, et al.Advances in Therapy|November 3, 2023
A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in PharmacovigilanceGanesh Kumar Vemula, Pavan Badale, Petros Mavrogenis, et al.Blood|January 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trialJoshua D Brody, Judit Jørgensen, David Belada, et al.Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.Pageof 2